Hamps Bio
BSE: HAMPS · Other Agricultural Products
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Hamps Bio's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Hamps Bio is an Indian pharmaceutical company that manufactures and markets a diverse range of formulations, including analgesics, antibiotics, and nutritional supplements. The company operates a manufacturing facility in Gujarat and provides both branded generics and contract manufacturing services.
Business Model
The company generates revenue through the sale of its own branded pharmaceutical products and by providing contract manufacturing services to domestic and international clients. It leverages its manufacturing capabilities to supply institutional chains and emerging markets.
Management Commentary
Management focuses on maintaining quality compliance and industry certifications to support its export operations and institutional supply chain presence.
Growth Outlook
Growth is expected to be driven by the expansion of export operations into emerging markets and the continued scaling of contract manufacturing services. The company aims to leverage its diverse dosage form portfolio to capture further market share.
Key Risks
- Regulatory Compliance Risk. Failure to maintain stringent quality certifications could lead to the suspension of export operations and loss of institutional contracts.
- Competitive Pricing Pressure. The pharmaceutical generics market is highly fragmented, which may compress profit margins due to intense price competition.
- Geopolitical and Export Risk. As the company targets emerging markets, it remains vulnerable to currency fluctuations and trade policy changes in those regions.
Start your research today
Unlock AI insights, financials, peers and live data on Hamps Bio and 5,000+ companies — free.
Peers · Other Agricultural Products
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Hamps BioHAMPS | ₹21 Cr | — | — | — | 0.4% | — | — | -55.0% |
Regaal ResourcesREGAAL | ₹950 Cr | 15.27 | 11.12 | — | 12.3% | 12.2% | 12.0% | -18.9% |
Sukhjit Starch & Chemicals LimitedSUKHJITS | ₹497 Cr | 14.53 | 7.51 | -0.9% | 7.5% | 6.2% | 10.2% | -3.8% |
Mangalam Global Enterprise LimitedMGEL | ₹476 Cr | 10.03 | 8.41 | 41.4% | 2.3% | 19.0% | 34.2% | -11.6% |
Modi NaturalsMODINATUR | ₹463 Cr | 9.15 | 8.36 | 8.5% | 10.4% | 34.2% | 28.4% | -28.0% |
Sarveshwar FoodsSARVESHWAR | ₹419 Cr | 6.18 | 9.33 | 16.4% | 5.1% | 8.4% | 17.4% | -53.9% |
As of Mar 2026
Financials
Hamps Bio
BSE: HAMPS · Other Agricultural Products
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Hamps Bio's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Hamps Bio is an Indian pharmaceutical company that manufactures and markets a diverse range of formulations, including analgesics, antibiotics, and nutritional supplements. The company operates a manufacturing facility in Gujarat and provides both branded generics and contract manufacturing services.
Business Model
The company generates revenue through the sale of its own branded pharmaceutical products and by providing contract manufacturing services to domestic and international clients. It leverages its manufacturing capabilities to supply institutional chains and emerging markets.
Management Commentary
Management focuses on maintaining quality compliance and industry certifications to support its export operations and institutional supply chain presence.
Growth Outlook
Growth is expected to be driven by the expansion of export operations into emerging markets and the continued scaling of contract manufacturing services. The company aims to leverage its diverse dosage form portfolio to capture further market share.
Key Risks
- Regulatory Compliance Risk. Failure to maintain stringent quality certifications could lead to the suspension of export operations and loss of institutional contracts.
- Competitive Pricing Pressure. The pharmaceutical generics market is highly fragmented, which may compress profit margins due to intense price competition.
- Geopolitical and Export Risk. As the company targets emerging markets, it remains vulnerable to currency fluctuations and trade policy changes in those regions.
Start your research today
Unlock AI insights, financials, peers and live data on Hamps Bio and 5,000+ companies — free.
Peers · Other Agricultural Products
As of Mar 2026